

# Hypoxia promotes temozolomide resistance in glioblastoma cells via ROS-mediated up-regulation of TRPM2

yibo Zhao

zybxdm@163.com

Army Medical University

dan peng

Daping Hospital

xiang feng zhu

Daping Hospital

Yongqing Cai

Daping Hospital

Kai-Yang Wang

Army Medical University

ziwei li

Daping Hospital

li li

Daping Hospital

li ning jiang

Daping Hospital

Jian-Hong Chen

Daping Hospital

---

## Research Article

**Keywords:** glioblastoma multiforme, hypoxia, temozolomide, chemoresistance, ROS, TRPM2

**Posted Date:** January 24th, 2024

**DOI:** <https://doi.org/10.21203/rs.3.rs-3886648/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Additional Declarations:** No competing interests reported.

---

# Abstract

**Background:** Hypoxia, an essential feature of gliomas, is thought to promote chemo-resistance by regulating reactive oxygen species (ROS) levels. Transient receptor potential melastatin 2 (TRPM2) is one of the ion transport proteins and is involved in the regulation of oxidative stress. However, relationship between ROS and TRPM2 expression in hypoxia-induced temozolomide (TMZ) resistance of glioblastoma cells remains unclear.

**Methods:** U87MG cells were cultured with different concentrations of TMZ for the indicated times under normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>). Cell viability was detected with WST-1 test and observed by a neurite outgrowth assay. The intracellular ROS scavenging activity was detected according to the H2DCF-DA method. The cells were also treated with the scavenger of ROS NAC and the inhibitor of TRPM2 2-APB. Impaired mitochondrial membrane potential ( $\Delta\Psi_m$ ) and intensity of intracellular Ca<sup>2+</sup> were measured under fluorescence microscope. Online database was used to assess the relationship between MGMT and TRPM2 expression level. Western blot was used to analyze the protein levels of TRPM2, MGMT, MSH3 and APNG.

**Results:** Compared with the normoxia group, hypoxia significantly promoted glioma cells survival after treatment by TMZ (200 $\mu$ M) for 24 h or 48 h, accompanied with reduction of mitochondrial dysfunction and intracellular ROS. However, the baseline levels of ROS were mildly increased under hypoxia, which had no impact on mitochondrial function in glioma cells. Additionally, TRPM2 expression was obviously increased under hypoxia and inhibited by NAC in glioma cells. We found that the expression levels of TRPM2 were positively correlated with MGMT both in online database ( $\rho=0.165$ ,  $P < 0.05$ ) and GBM cancer tissues ( $r=0.9302$ ,  $P < 0.05$ ). Over-expression of TRPM2 participated in the up-regulation of APNG and MGMT, but down-regulation of MSH3 in glioma cells under hypoxia. Our findings also demonstrated that the treatment group during NAC or 2-APB add-on could significantly attenuate calcium influx, followed by increasing mitochondrial dysfunction and cytotoxicity in glioma cells, in comparison with TMZ alone.

**Conclusion:** The hypoxia-induced up-regulation of baseline ROS levels contributes to the decrease in the sensitivity of glioma cells to TMZ via promoting demethylation and inhibiting DNA mismatch repair. Moreover, TRPM2-mediated Ca<sup>2+</sup> influx attenuates mitochondria dysfunction and then protects glioma cells against TMZ damage. TRPM2 may be a potential target in adjuvant treatment with TMZ for glioblastoma multiforme (GBM) patients.

## Introduction

Glioblastoma multiforme (GBM) is the most common and aggressive intracranial tumor in adults, and the 5-year mortality of that was next only to pancreatic and lung cancer (Louis et al., 2016). The current standard therapies for newly diagnosed GBM patients include surgery, post-operative radiotherapy, and temozolomide (TMZ) treatment (Wu et al., 2021). TMZ belongs to the second generation of an oral

alkylating agent and serves as the first-line chemotherapeutic agent of GBM patients. Unfortunately, more than half of GBM patients have poor prognosis and overall survival due to TMZ resistance, which has become the main obstacle for successful treatment in GBM patients (Fabian et al., 2019). Hence, it is important to investigate the mechanisms of TMZ resistance for developing new therapeutic drugs.

In vivo, TMZ is first converted into the active metabolite MTIC, which is further decomposed into 5-aminoimidazole-4-amide (AIC) and diazomethane. Diazomethane alters DNA or RNA at N<sup>7</sup> and O<sup>6</sup> sites on guanine and the N<sup>3</sup> on adenine through the addition of methyl groups, followed by inducing cell death. DNA mismatch repair (MMR) is helpful for tumor cells sensitive to TMZ via fixation of the methylated sites. In contrast, the demethylation of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) and the N<sup>7</sup> methylated sites removed by alkylpurine-DNA-N-glycosylase (APNG) could alleviate the damage of TMZ to tumor cells (Agnihotri et al., 2012; Happold et al., 2012; Nam et al., 2021). Accordingly, over-expression of MGMT and APNG and/or deficiency of MMR were considered to mainly participate in the resistance of tumor cells to TMZ.

Hypoxia occurs not only in natural environments such as high altitudes, underground caves, and deep seas, but also in human pathological conditions, such as hypoxic solid tumors (Jiang et al., 2021). Tumor cells are exposed to hypoxia microenvironment as the insufficient distribution of blood vessels. Hypoxia plays a key role in the resistance to chemotherapy, immunotherapy and radiotherapy through multiple mechanisms such as dysregulation of DNA repair system, anti-apoptosis, and drug efflux (Minassian et al., 2019; Weng et al., 2022). It also potentially results in poor prognosis for cancer patients with chemotherapy. Previous studies have reported that hypoxia was related with resistance to TMZ in glioblastoma (Chen et al., 2015; Gao et al., 2019; Hsieh et al., 2015; Monteiro et al., 2017). However, the exact mechanisms of hypoxia-induced TMZ resistance are incompletely understood.

Hypoxia exhibited a greater level of reactive oxygen species (ROS) mainly due to vigorous metabolism and mitochondrial dysfunction in malignant cells (Prasad et al., 2017). Interestingly, ROS was considered as a double-edged sword. The physiological ROS levels contributed to the proliferation, migration and differentiation of tumor cells, while the lethal ROS levels could lead to DNA damage and cell death (Cheng et al., 2013; Wang et al., 2013). ROS was related to chemo-resistance in some tumor cells (Ledoux et al., 2003; Stieg et al., 2022). Therefore, it is essential for illuminating the effect of ROS on glioma cells and its underlying mechanisms involved in drug resistance.

Transient receptor potential melastatin 2 (TRPM2) belongs to the ion transport protein family, including sodium, potassium and calcium ion channels, and highly expresses in several cancers (Wang et al., 2020). Calcium channels embedded in cell membrane were gated by activation of TRPM2, which could be up-regulated with oxidative stress such as ROS or hydrogen peroxide (Naziroglu, 2012; Wehage et al., 2002; Ye et al., 2023; Zhu et al., 2018). In SH-SY5Y neuronal cells, hypoxia-induced increased levels of ROS also positively motivate the function of TRPM2 channel (Akyuva and Naziroglu, 2020). However, few studies reported the relevance between ROS and TRPM2 in glioma cells.

It is very complicated about the physiologic and pathophysiologic role of  $\text{Ca}^{2+}$  influx into the cells. Naziroglu M indicated that enhancement of intracellular  $\text{Ca}^{2+}$  contributed to DNA repair, chem-resistance and cell survival (Naziroglu, 2007). Paradoxically, Zhu J suggested that  $\text{Ca}^{2+}$  influx could induce apoptosis in hepatocellular carcinoma cells (Zhu et al., 2018). Thus, it is necessary to understand the relationship of  $\text{Ca}^{2+}$  entry with drug resistance in glioma cells. In the present study, we aimed to analyze the effect of ROS and TRPM2 on TMZ resistance and reveal the underlying mechanisms in glioma cells.

## Materials and methods

### Reagents

Temozolomide (TMZ) was purchased from Selleck Chemicals (Shanghai, China). Anti-TRPM2 antibody (#ab11168) and Anti-APNG (#ab55461) were purchased from Abcam Biotechnology (San Francisco, USA). 2-Aminoethyl diphenylborinate (#D9754), Anti-GAPDH (#G2267), Anti-MGMT (#SAB2105451) and Anti-MSH3 (#SAB4501924) antibodies were obtained from Sigma-Aldrich (St. Louis, MO, USA). Olaparid (#HY-10162) and N-acetyl-L-cysteine (NAC) (#HY-B0215) were purchased from MedChemExpress (Monmouth Junction, USA).  $\beta$ -actin antibody (#B2315) and all secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TEMED (#ST728), 10% SDS (#ST628), WB primary antibody diluent (#P0023A), Cell Lysis buffer (#P0013) and BCA protein assay kit (#P0012) were purchased from Beyotime Biotechnology (Shanghai, China). Immobilon Western Chemilum HRP Substrate was purchased from Millipore (Billerica, USA). All other reagents were from Sigma-Aldrich, unless otherwise indicated.

### Cell culture

U87MG cell line was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and incubated in DMEM/HIGH Glucose (HyClone-Pierce, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, USA) and antibiotics (100 U/mL penicillin and 100  $\mu\text{g}/\text{mL}$  streptomycin) in hypoxia (2.5%  $\text{O}_2$  + 5%  $\text{CO}_2$  + 92.5%  $\text{N}_2$ ) or a 5%  $\text{CO}_2$  atmosphere at 37°C with or without TMZ.

### Tissues

Glioblastoma multiforme tissues were obtained from the Department Oncology of Daping Hospital of Army Medical University (Chongqing, China). In this study, we analyzed the viable samples of cancer tissues (WHO grade IV) from ten patients treated with TMZ, who signed informed consent forms. The study was approved by the Ethics Committee of Daping Hospital of Army Medical University and conformed to the Declaration of Helsinki.

### Assessment of cell proliferation

WST-1 Cell Proliferation and Cytotoxicity Assay Kit (Beyotime, China) was applied to detect the effects of TMZ treatment on the viability of U87MG cells under normoxia (21%  $\text{O}_2$ ) or hypoxia (2.5%  $\text{O}_2$ ). U87MG cells ( $6 \times 10^3/\text{mL}$ ) cells were planted in 96-well plates and treated with different concentrations of TMZ (0,

25, 50, 100, 200, 400, 800  $\mu\text{M}$ ) for 24 hours. The culture supernatants were collected, and then 10  $\mu\text{L}$  WST-1 solution was added to each well, followed by incubating for 2–3 hours under normoxia or hypoxia. Optical density (OD) was measured at 450nm on a microplate reader (Gene company limited, Hong Kong China). The cell viability was shown as the percentage of the control.

U87MG cells ( $6 \times 10^3/\text{mL}$ ) were seeded in 96-well plates and incubated for 24 hours under normoxia (21%  $\text{O}_2$ ) and hypoxia (2.5%  $\text{O}_2$ ). The samples were treated with TMZ (200  $\mu\text{M}$ ) for different time points (0, 6, 12, 24, 48 and 72 hours). The cell viability was measured and calculated as described above.

## **Assessment of reactive oxygen species (ROS) level**

The intracellular levels of ROS were detected by reactive oxygen species assay kits (ROS Assay Kit) (Beyotime, China). Briefly, U87MG cells were plated in 6-well plates at a density of  $1.0 \times 10^4$  for the indicated time points under normoxia (21%  $\text{O}_2$ ) or hypoxia (2.5%  $\text{O}_2$ ), and then TMZ (200  $\mu\text{M}$ ) was added to treat for 24 and 48 hours at 37°C. The culture medium was removed and the samples were rinsed with PBS. 10  $\mu\text{M}$  2',7'-dichlorofluorescein diacetate (H2DCF-DA) was added to co-incubate for 30 minutes, and fluorescence was obtained by Thermo VarioskanFlash (excitation at 488 nm and emission at 525 nm). ImageJ 1.46r software (Wayne Rasband, National Institutes of Health, USA) was used to quantitatively analyze the mean fluorescence intensity (MFI) of DCFH-DA.

## **Measurement of mitochondrial membrane potential ( $\Delta\Psi\text{m}$ )**

U87MG cells were plated in 6-well plates at a density of  $1.0 \times 10^4$  for 48 hours and then incubated with TMZ (200  $\mu\text{M}$ ) at 37°C for the indicated time points (24 and 48 hours) under normoxia (21%  $\text{O}_2$ ) or hypoxia (2.5%  $\text{O}_2$ ). According to the operational approaches of the mitochondrial membrane potential assay kit with JC-1 (Beyotime, China), 1 ml JC-1 staining solution was added to each well and incubated with U87MG cells for 20 min at 37°C. The culture medium was sucked off and the cells were washed for 2 times with JC-1 staining buffer (1X). Afterwards, 2ml of culture medium was added, and the fluorescence of cells was visioned under the fluorescence microscope (IX71, Olympus, Japan) with an imaging system (CellSens Standard, V4.2.1, Japan).

## **Measurement of intracellular $\text{Ca}^{2+}$ ( $[\text{Ca}^{2+}]_i$ )**

U87MG ( $6 \times 10^3/\text{mL}$ ) were seeded in 12-well plates for 24 hours under normoxia (21%  $\text{O}_2$ ) or hypoxia (2.5%  $\text{O}_2$ ). In normoxia groups, the cells were respectively incubated with PBS and TMZ (200  $\mu\text{M}$ ) alone for 48 hours. Under hypoxia condition, the cells were respectively treated with PBS, TMZ (200  $\mu\text{M}$ ) alone, TMZ (200  $\mu\text{M}$ ) plus 2-APB (100  $\mu\text{M}$ ) and TMZ (200  $\mu\text{M}$ ) plus NAC (100  $\mu\text{M}$ ) for 48 hours. 5  $\mu\text{M}$  Fluo-3 AM (Beyotime, China) was incubated with the samples for 60 minutes at 37°C, and then cleaned with PBS. Furthermore, the samples were observed under the fluorescence microscope (IX71, Olympus, Japan). The excitation wavelength was 506 nm, and the emission wavelength was 526 nm.

## **Neurite outgrowth assay**

U87MG cells were plated in a 24-well plate at a density of  $6 \times 10^3$  and exposed to 2.5% O<sub>2</sub> for 24 h. Hypoxic cells were respectively co-incubated with PBS, TMZ (200 μM), NAC(100 μM), 2-APB (100 μM), TMZ (200 μM) plus 2-APB (100 μM) and TMZ (200 μM) plus NAC (100 μM) for additional 24 h. The culture supernatants were absorbed out and 200 μL 4% paraformaldehyde was added to fix cell morphology. Cell images were observed under the inverted microscope (CKX41, Olympus, Japan) and 10 fields (200×) were randomly selected to analyze per group.

## **Bioinformatics analysis of MGMT and TRPM2 expression**

The Tumor Immune Estimation Resource 2.0 (TIMER 2.0) (T. Li et al., 2017) was used to assess the relationship between MGMT and TRPM2 expression level in public databases among different cancer groups. Data from tumor tissues were obtained from The Cancer Genome Atlas (TCGA) Research Network (<https://www.cancer.gov/tcga>). These datasets are publicly available. All the procedures were performed in accordance with the relevant guidelines and regulations. The correlation analysis included all 40 cancer types available at TIMER 2.0. Statistical analysis was performed with Pearson test (\*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001).

## **Western blot**

Total proteins were extracted and their concentrations were measured by BCA protein assay kit (Beyotime, China). Total proteins (30–50 μg) were separated by 10% SDS-polyacrylamide gel electrophoresis (Bio-Rad Laboratories, Inc., USA) and transferred to 0.2 μm PVDF membranes (Millipore, USA). The membranes were blocked for 2 h in 5% in Tris-buffered saline containing a non-fat dry milk solution and then incubated with appropriate primary antibodies overnight at 4°C. Dilutions of the primary antibodies were as follows: 1:300 for anti-TRPM2 antibody, 1:500 for anti-MGMT, anti-APNG and anti-MSH3 antibody, 1:1000 for anti-GADPH and β-Actin antibody. Specific protein bands were visualized with ChemiDoc™ Imaging System (Bio-Rad Laboratories Inc., USA) according to the manufacturer's protocol. The gray density of the protein bands were determined by the Image J software (National Institutes of Health, Bethesda, MD, USA) and data were presented as the percentage of the control.

## **Statistic analysis**

All experiments were performed at least three times, and the results were expressed as the mean ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism version 5 for Windows (GraphPad Software, San Diego, CA). Quantitative analysis of the length of neurite was measured by ImageJ 1.48u. The results were analyzed by one-way analysis of variance (ANOVA) followed by an SNK-q test for multiple comparisons. P < 0.05 was considered to be statistically significant.

## **Results**

### **Hypoxia induces the resistance of glioma cells to TMZ**

Hypoxia is known to cause resistance to chemotherapy in tumor cells (Yang et al., 2022). Firstly, to observe the effects of TMZ on glioma cells under hypoxia and normoxia, U87MG cells are treated by TMZ for 24h, and the concentration of that ranges from 0 to 800  $\mu\text{M}$ . Our data indicated that hypoxia obviously increased the cell viability of U87MG cells treated with TMZ from 100 to 800  $\mu\text{M}$ , compared with the normoxia group (Fig. 1A). Subsequently, the proliferation rate in the presence of TMZ (200  $\mu\text{M}$ ) was detected at different time points, and the results demonstrated that hypoxia significantly decreased glioma cells sensitivity to TMZ from 24 to 72 h (Fig. 1B).

## **Hypoxia ameliorates the sensitivity of glioma cells to TMZ via inhibition of mitochondrial dysfunction**

In addition, we detected the changes of mitochondrial membrane potential ( $\Delta\Psi\text{m}$ ) in U87MG cells treated with TMZ (200  $\mu\text{M}$ ) at different time points via JC-1 staining under hypoxia and normoxia. The JC-1 green staining percentage of U87MG cells without TMZ under hypoxia has no significant difference with that of the normoxic group (Fig. 1C and 1D). However, after incubating with TMZ from 24 to 48h, the JC-1 green staining percentage of U87MG cells under hypoxia was higher than that of the normoxia group (0 hour) and obviously decreased in comparison with the normoxia group at the same time points (Fig. 1C and 1D).

### **Hypoxia increases the baseline ROS levels in glioma cells, but down-regulates ROS generation of that exposed to TMZ**

Mitochondria are one of the main organelles to produce ROS in cells (Zelentsova et al., 2022). In order to analyze the effects of hypoxia on ROS generation in glioma cells, the H<sub>2</sub>DCF-DA method was used to detect intracellular ROS levels. As presented in Fig. 1E, after treatment of TMZ from 24 to 48h under hypoxia and normoxia, the intracellular ROS scavenging activity was significantly enhanced than that of the normoxia group (0 hour), and hypoxia markedly alleviates the intracellular ROS levels, compared with normoxia group at the same time points. These results indicate that although inducing the up-regulation of baseline ROS levels in glioma cells, hypoxia decreases the sensitivity of that to TMZ through attenuating ROS production and mitochondrial damage.

## **ROS is involved in up-regulation of TRPM2 under hypoxia in glioma cells**

To explore the relationship between the up-regulation of baseline ROS levels and hypoxia-induced TMZ resistance in glioma cells, the results of future studies showed the intracellular ROS scavenging activity was significantly elevated in a time-dependent manner from 6 to 72 hours, but it has no obvious difference under normoxia (Fig. 2A). Previous studies have also indicated that TRPM2 was the potential downstream targets of ROS in tumor cells (Hirschler-Laszkiwicz et al., 2018). To explore the relevance of ROS in regulating TRPM2 expression in glioma cells, the ROS and TRPM2 expression levels were respectively measured by WST-1 kit and Western blot. TRPM2 expression was gradually up-regulated in a



time-dependent manner under hypoxia within 24 hours (Fig. 2B and 2C). As presented in Fig. 2D and 2E, in the presence or absence of NAC pretreatment, hypoxia significantly increased TRPM2 expression compared to the normoxia group. However, the expression of TRPM2 was obviously decreased in U87MG cells exposed to NAC (a scavenger of ROS) under hypoxia. The results demonstrated that the baseline intracellular ROS levels were enhanced by hypoxia and positively relevant to the over-expression of TRPM2 in glioma cells.

## **The up-regulation of TRPM2 induced by hypoxia is vital for TMZ resistance**

MGMT was considered to be a key protein for TMZ resistance in GBM patients (Wang et al., 2023). To analyze whether hypoxia promotes TMZ resistance to glioma cells via the TRPM2 pathway, we first analyzed the relationship between MGMT and TRPM2 protein expression in GBM groups in the TIMER 2.0 database, then these samples from cancer tissues of GBM patients and U87MG cells were detected by Western blot. In the TIMER 2.0 database, we examined whether there was a correlation between MGMT and TRPM2 in 40 types of cancer, and found a positive trend in the GBM group (n = 153) (Fig. 3A - B). Next, we found that TRPM2 and MGMT proteins were expressed in all five specimens of GBM patients (Fig. 4A). As shown in Fig. 4B, the expression level of MGMT was elevated with up-regulation of TRPM2 in specimens ( $r = 0.9302$ ,  $P < 0.05$ ).

To further explore the mechanisms of TRPM2 in hypoxia-induced TMZ resistance, the protein levels of MSH3, APNG and MGMT were detected by Western blot in glioma cells treated with or without 2-APB (inhibitor of TRPM2) pretreatment. The expression levels of APNG and MGMT were obviously enhanced, while that of MSH3 was alleviated under hypoxia, in comparison with the normoxia group (Fig. 4D - F). Moreover, after treatment with 2-APB, protein levels of APNG and MGMT were reduced, but that of MSH3 was over-expressed in U87MG cells under hypoxia (Fig. 4D - F). Thus, the results demonstrate that the increased expression of TRPM2 was related to hypoxia-induced TMZ resistance in glioma cells.

## **Hypoxia protects mitochondrial function via TRPM2-dependent calcium influx induced by ROS**

To further analyze the mechanism of TRPM2 in TMZ resistance under hypoxia, the intracellular calcium was observed by fluorescence microscope. The  $Ca^{2+}$  concentrations in cells treated with TMZ were significantly increased under hypoxia, compared with the normoxia group (Fig. 5A and 5C). Furthermore, under hypoxia condition, U87MG cells treated with TMZ plus NAC or 2-APB executes less intracellular  $Ca^{2+}$  concentrations than TMZ alone, respectively (Fig. 5A and 5C). In addition, the mitochondrial membrane potential ( $\Delta\Psi_m$ ) in U87MG cells treated with TMZ plus NAC or 2-APB was significantly alleviated, compared to TMZ alone under hypoxia, respectively (Fig. 5B and 5D). These findings demonstrate that ROS and TRPM2 participated in calcium influx, which contributed to inhibiting the mitochondrial dysfunction induced by TMZ in glioma cells.

# Hypoxia decreases the TMZ-induced cytotoxicity through ROS-regulated increases of TRPM2 in glioma cells

To further verify the relevance of ROS and TRPM2 in TMZ resistance, neurite outgrowth assay was used to evaluate the effects of NAC and 2-APB on the toxicity of TMZ for neurites in U87MG cells under hypoxia. Our results indicated that the neurite length of U87MG cells treated with TMZ alone was significantly shorter than the control group (Fig. 6A and 6B). Moreover, compared with TMZ alone, the neurite length was markedly decreased in U87MG cells treated with TMZ plus NAC or 2-APB and increased in cells treated with NAC or 2-APB alone, respectively (Fig. 6B). These findings demonstrate that ROS and TRPM2 are implicated in decreasing the cytotoxicity of TMZ to glioma cells.

## Discussion

Whether it is in the plateau environment or in the human microenvironment, how to skillfully balance the impact of hypoxia on the body has always been a hot topic of scientific research. Hypoxia is one of the representative features in the tumor microenvironment (TME) and is caused by the inadequate supply of blood and oxygen with the rapid expansion of tumor cells (Shao et al., 2018). The oxygen pressure levels are evidently lower in tumor tissues than in normal tissues. In order to adapt with the anoxic environment, tumor cells could tend to be more aggressive and induce resistant tumor phenotypes (Roma-Rodrigues et al., 2019). Tumor metastasis has remained the primary reason for death in GBM patients. It has been reported that hypoxia was associated with drug resistance in cancer patients and could facilitate invasions of tumor cells into the healthy brain regions (Jensen et al., 2014; Kaur et al., 2005). Consistent with the previous studies (Ge et al., 2018), we also demonstrated that hypoxia exposure (2.5% O<sub>2</sub>) contributes to decreasing the sensibility of glioma cells to TMZ, compared with the normoxia group. However, the molecular mechanisms of TMZ resistance to GBM under hypoxia is not entirely clear.

Owing to lack of oxygen in tumor tissues, ROS levels are commonly higher than that of normal tissues (Syu et al., 2016). The mild up-regulation of ROS was beneficial for cell proliferation and promoted drug resistance to cancer cells such as breast cancer and choriocarcinoma cells (Shen et al., 2015; Zhu and Zuo, 2013). Interestingly, excessive ROS could damage cellular biomolecules including proteins, DNA, and RNA, followed by inducing cell apoptosis and death in tumor cells. In this study, we demonstrated that TMZ significantly increased mitochondria dysfunction and intracellular ROS levels under hypoxia or normoxia, while suppressing the viability of glioma cells, suggesting that excessive ROS executes negative impacts on proliferation of glioma cells. In addition, our results also found that hypoxia induced the increasing level of baseline ROS and had no effects on mitochondria functions in glioma cells untreated by TMZ. Therefore, we speculated that hypoxia-induced mild up-regulation of ROS might be associated with the lower sensitivity of glioma cells to TMZ, but the underlying mechanisms remained unclear.

The TRPM2 channel is widely expressed in many different types of cells. In the brain, TRPM2 expression has been reported in hippocampus(X. Li et al., 2017), cortex(Kaneko et al., 2006), striatum (Hill et al., 2006) and astrocytes, especially in microglial cells(Lee et al., 2010;Wang et al., 2016). In our studies, we found that, compared with the normoxia group, hypoxia markedly promoted TRPM2 expression in glioma cells, in a time-dependent manner. Moreover, NAC evidently inhibited TRPM2 expression under hypoxia, indicating that ROS contributed to up-regulation of TRPM2 protein in glioma cells, which was consistent with the results of previous studies (Hiroi et al., 2013;Jiang et al., 2010). In addition, our results also showed that TRPM2 expression was positively related to MGMT in cancer tissues of GBM patients. The previous studies reported that hypoxia induces TMZ resistance via over-expression of ZEB1 and c-MYB, which could lead to up-regulation of MGMT protein in GBM cells in vitro(Joseph et al., 2015;Siebzehnrubl et al., 2013). Consistently, our results demonstrated that TRPM2 promoted the expression of MGMT and APNG, but inhibited the mismatch repair of DNA under hypoxia in glioma cells. Based on these findings, we concluded that ROS-mediated over-expression of TRPM2 should be related to hypoxia-induced TMZ resistance in GBM cells.

TRPM2 belongs to a key protein for  $Ca^{2+}$  entry. The changes in intracellular  $Ca^{2+}$  levels were vital for the proliferation or death of cancer cells. It has been reported that  $Ca^{2+}$  influx induced by T-type or TRP (transient receptor potential) channels was conducive to cell proliferation in breast and prostate cancer (Du J et al., 2009;Panner and Wurster, 2006). In our research, we found that hypoxia contributes to  $Ca^{2+}$  influx in glioma cells, in comparison with the normoxia group. Consistent with the previous studies(Bomben and Sontheimer, 2008), our data presented that 2-APB blocked the entry of intracellular  $Ca^{2+}$  and increased mitochondria dysfunction induced by TMZ, indicating that TRPM2-regulated  $Ca^{2+}$  influx was positively corrected with hypoxia-induced resistance to TMZ. Compared with TMZ alone, the treatment group during NAC add-on decreased significantly the concentration of intracellular  $Ca^{2+}$  and mitochondria function, suggesting that ROS is important for TRPM2-regulated  $Ca^{2+}$  influx. In addition, our results were also verified by a neurite outgrowth assay that ROS and TRPM2 protein were related with hypoxia-induced TMZ resistance in glioma cells.

In conclusion, our findings suggested that the intracellular levels of ROS and TRPM2 protein were up-regulated in glioma cells under hypoxia, which can further reduce the sensitivity to TMZ via promoting demethylation and inhibiting DNA mismatch repair. Moreover, TRPM2-mediated  $Ca^{2+}$  influx attenuated mitochondria dysfunction, and then protected glioma cells against TMZ injury. TRPM2 may be a potential target in adjuvant therapy with TMZ for GBM patients.

## Declarations

## FUNDING

This research was funded by the project of The Innovation Ability Improvement Program of Medical Personnel of the Army Medical Center (No. 130333) and Chongqing postgraduate education "curriculum

ideological and political" demonstration project (No. YKCSZ23057).

## Author Contribution

Conceptualization, Peng D. and Zhao Y.B.; methodology, Cai Y.Q.; validation, Li L.; formal analysis, Jiang L.N.; resources, Zhu X.F.; writing—original draft preparation, Peng D. and Zhao Y.B.; writing—review and editing, Cai Y.Q.; visualization, Wang K.Y.; project administration, Li Z.W.; funding acquisition, Chen J.H.. All authors have read and agreed to the published version of the manuscript.

## References

1. Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Diefes, K. L., Mischel, P. S., Kelly, J., McGown, G., Thorncroft, M., Carlson, B. L., Sarkaria, J. N., Margison, G. P., Aldape, K., Hawkins, C., Hegi, M., Guha, A. (2012). Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. *J Clin Invest*, 122(1), 253–266. doi: 10.1172/JCI59334
2. Akyuva, Y., Naziroglu, M. (2020). Resveratrol attenuates hypoxia-induced neuronal cell death, inflammation and mitochondrial oxidative stress by modulation of TRPM2 channel. [Journal Article]. *Sci Rep*, 10(1), 6449. doi: 10.1038/s41598-020-63577-5
3. Bomben, V. C., Sontheimer, H. W. (2008). Inhibition of transient receptor potential canonical channels impairs cytokinesis in human malignant gliomas. [Journal Article; Research Support, N.I.H., Extramural]. *Cell Prolif*, 41(1), 98–121. doi: 10.1111/j.1365-2184.2007.00504.x
4. Chen, W. L., Wang, C. C., Lin, Y. J., Wu, C. P., Hsieh, C. H. (2015). Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. [Journal Article; Research Support, Non-U.S. Gov't]. *J Transl Med*, 13, 389. doi: 10.1186/s12967-015-0758-8
5. Cheng, C. W., Kuo, C. Y., Fan, C. C., Fang, W. C., Jiang, S. S., Lo, Y. K., Wang, T. Y., Kao, M. C., Lee, A. Y. (2013). Overexpression of Lon contributes to survival and aggressive phenotype of cancer cells through mitochondrial complex I-mediated generation of reactive oxygen species. [Journal Article; Research Support, Non-U.S. Gov't]. *Cell Death Dis*, 4(6), e681. doi: 10.1038/cddis.2013.204
6. Du J, Xie, J., Yue, L. (2009). Intracellular calcium activates TRPM2 and its alternative spliced isoforms. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. *Proc Natl Acad Sci U S A*, 106(17), 7239–7244. doi: 10.1073/pnas.0811725106
7. Fabian, D., Guillermo, P. E. M., Alnahhas, I., Sebastian, N., Giglio, P., Pudevalli, V., Gonzalez, J., Palmer, J. D. (2019). Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. [Journal Article; Review]. *Cancers (Basel)*, 11(2). doi: 10.3390/cancers11020174
8. Gao, Y., Liu, B., Feng, L., Sun, B., He, S., Yang, Y., Wu, G., E, G., Liu, C., Gao, Y., Zhang, E., Zhu, B. (2019). Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic

- Glioblastoma. [Journal Article]. *Front Oncol*, 9, 33. doi: 10.3389/fonc.2019.00033
9. Ge, X., Pan, M. H., Wang, L., Li, W., Jiang, C., He, J., Abouzid, K., Liu, L. Z., Shi, Z., Jiang, B. H. (2018). Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. *Cell Death Dis*, 9(11), 1128. doi: 10.1038/s41419-018-1176-7
  10. Happold, C., Roth, P., Wick, W., Schmidt, N., Florea, A. M., Silginer, M., Reifenberger, G., Weller, M. (2012). Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. [Journal Article; Research Support, Non-U.S. Gov't]. *J Neurochem*, 122(2), 444–455. doi: 10.1111/j.1471-4159.2012.07781.x
  11. Hill, K., Tigue, N. J., Kelsell, R. E., Benham, C. D., McNulty, S., Schaefer, M., Randall, A. D. (2006). Characterisation of recombinant rat TRPM2 and a TRPM2-like conductance in cultured rat striatal neurones. [Journal Article; Research Support, Non-U.S. Gov't]. *Neuropharmacology*, 50(1), 89–97. doi: 10.1016/j.neuropharm.2005.08.021
  12. Hiroi, H., Momoeda, M., Watanabe, T., Ito, M., Ikeda, K., Tsutsumi, R., Hosokawa, Y., Koizumi, M., Zenri, F., Muramatsu, M., Taketani, Y., Inoue, S. (2013). Expression and regulation of transient receptor potential cation channel, subfamily M, member 2 (TRPM2) in human endometrium. [Journal Article]. *Mol Cell Endocrinol*, 365(2), 146–152. doi: 10.1016/j.mce.2012.10.015
  13. Hirschler-Laszkiwicz, I., Chen, S. J., Bao, L., Wang, J., Zhang, X. Q., Shanmughapriya, S., Keefer, K., Madesh, M., Cheung, J. Y., Miller, B. A. (2018). The human ion channel TRPM2 modulates neuroblastoma cell survival and mitochondrial function through Pyk2, CREB, and MCU activation. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. *Am J Physiol Cell Physiol*, 315(4), C571-C586. doi: 10.1152/ajpcell.00098.2018
  14. Hsieh, C. H., Lin, Y. J., Wu, C. P., Lee, H. T., Shyu, W. C., Wang, C. C. (2015). Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. [Journal Article; Research Support, Non-U.S. Gov't]. *Clin Cancer Res*, 21(2), 460–470. doi: 10.1158/1078-0432.CCR-14-0618
  15. Jensen, R. L., Mumert, M. L., Gillespie, D. L., Kinney, A. Y., Schabel, M. C., Salzman, K. L. (2014). Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. [Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. *Neuro Oncol*, 16(2), 280–291. doi: 10.1093/neuonc/not148
  16. Jiang, L. H., Yang, W., Zou, J., Beech, D. J. (2010). TRPM2 channel properties, functions and therapeutic potentials. [Journal Article; Research Support, Non-U.S. Gov't; Review]. *Expert Opin Ther Targets*, 14(9), 973–988. doi: 10.1517/14728222.2010.510135
  17. Jiang, X., He, Y., Shen, Q., Duan, L., Yuan, Y., Tang, L., Shi, Y., Liu, B., Zhai, H., Shi, P., Yang, C., Chen, Y. (2021). RETSAT Mutation Selected for Hypoxia Adaptation Inhibits Tumor Growth. [Journal Article]. *Front Cell Dev Biol*, 9, 744992. doi: 10.3389/fcell.2021.744992

18. Joseph, J. V., Conroy, S., Pavlov, K., Sontakke, P., Tomar, T., Eggens-Meijer, E., Balasubramanian, V., Wagemakers, M., den Dunnen, W. F., Kruyt, F. A. (2015). Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1alpha-ZEB1 axis. [Journal Article; Research Support, Non-U.S. Gov't]. *Cancer Lett*, 359(1), 107–116. doi: 10.1016/j.canlet.2015.01.010
19. Kaneko, S., Kawakami, S., Hara, Y., Wakamori, M., Itoh, E., Minami, T., Takada, Y., Kume, T., Katsuki, H., Mori, Y., Akaike, A. (2006). A critical role of TRPM2 in neuronal cell death by hydrogen peroxide. [Journal Article; Research Support, Non-U.S. Gov't]. *J Pharmacol Sci*, 101(1), 66–76. doi: 10.1254/jphs.fp0060128
20. Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., Van Meir, E. G. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. [Journal Article; Research Support, U.S. Gov't, P.H.S.; Review]. *Neuro Oncol*, 7(2), 134–153. doi: 10.1215/S1152851704001115
21. Ledoux, S., Yang, R., Friedlander, G., Laouari, D. (2003). Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. [Journal Article; Research Support, Non-U.S. Gov't]. *Cancer Res*, 63(21), 7284–7290
22. Lee, M., Cho, T., Jantaratnotai, N., Wang, Y. T., McGeer, E., McGeer, P. L. (2010). Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. [Journal Article; Research Support, Non-U.S. Gov't]. *FASEB J*, 24(7), 2533–2545. doi: 10.1096/fj.09-149997
23. Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., Liu, X. S. (2017). TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. [Journal Article]. *Cancer Res*, 77(21), e108-e110. doi: 10.1158/0008-5472.CAN-17-0307
24. Li, X., Yang, W., Jiang, L. H. (2017). Alteration in Intracellular Zn(2+) Homeostasis as a Result of TRPM2 Channel Activation Contributes to ROS-Induced Hippocampal Neuronal Death. [Journal Article]. *Front Mol Neurosci*, 10, 414. doi: 10.3389/fnmol.2017.00414
25. Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. [Journal Article; Review]. *Acta Neuropathol*, 131(6), 803–820. doi: 10.1007/s00401-016-1545-1
26. Minassian, L. M., Cotechini, T., Huitema, E., Graham, C. H. (2019). Hypoxia-Induced Resistance to Chemotherapy in Cancer. [Journal Article]. *Adv Exp Med Biol*, 1136, 123–139. doi: 10.1007/978-3-030-12734-3\_9
27. Monteiro, A. R., Hill, R., Pilkington, G. J., Madureira, P. A. (2017). The Role of Hypoxia in Glioblastoma Invasion. [Journal Article; Review]. *Cells*, 6(4). doi: 10.3390/cells6040045
28. Nam, H. J., Kim, Y. E., Moon, B. S., Kim, H. Y., Jung, D., Choi, S., Jang, J. W., Nam, D. H., Cho, H. (2021). Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma. [Journal Article]. *iScience*, 24(3), 102238. doi: 10.1016/j.isci.2021.102238
29. Naziroglu, M. (2007). New molecular mechanisms on the activation of TRPM2 channels by oxidative stress and ADP-ribose. [Journal Article; Review]. *Neurochem Res*, 32(11), 1990–2001. doi:

10.1007/s11064-007-9386-x

30. Naziroglu, M. (2012). Molecular role of catalase on oxidative stress-induced Ca(2+) signaling and TRP cation channel activation in nervous system. [Journal Article; Review]. *J Recept Signal Transduct Res*, 32(3), 134–141. doi: 10.3109/10799893.2012.672994
31. Panner, A., Wurster, R. D. (2006). T-type calcium channels and tumor proliferation. [Journal Article; Review]. *Cell Calcium*, 40(2), 253–259. doi: 10.1016/j.ceca.2006.04.029
32. Prasad, S., Gupta, S. C., Tyagi, A. K. (2017). Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. [Journal Article; Review]. *Cancer Lett*, 387, 95–105. doi: 10.1016/j.canlet.2016.03.042
33. Roma-Rodrigues, C., Mendes, R., Baptista, P. V., Fernandes, A. R. (2019). Targeting Tumor Microenvironment for Cancer Therapy. [Journal Article; Review]. *Int J Mol Sci*, 20(4). doi: 10.3390/ijms20040840
34. Shao, C., Yang, F., Miao, S., Liu, W., Wang, C., Shu, Y., Shen, H. (2018). Role of hypoxia-induced exosomes in tumor biology. [Journal Article; Research Support, Non-U.S. Gov't; Review]. *Mol Cancer*, 17(1), 120. doi: 10.1186/s12943-018-0869-y
35. Shen, Y., Yang, J., Zhao, J., Xiao, C., Xu, C., Xiang, Y. (2015). The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: A survival mechanism in methotrexate-resistant choriocarcinoma cells. [Journal Article; Research Support, Non-U.S. Gov't]. *Exp Cell Res*, 334(2), 207–218. doi: 10.1016/j.yexcr.2015.04.010
36. Siebzehnruhl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnruhl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., Nabils, N. H., Kladd, M. P., Suslov, O., Brabletz, S., Brabletz, T., Reynolds, B. A., Steindler, D. A. (2013). The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. *EMBO Mol Med*, 5(8), 1196–1212. doi: 10.1002/emmm.201302827
37. Stieg, D. C., Wang, Y., Liu, L. Z., Jiang, B. H. (2022). ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance. [Journal Article; Review]. *Int J Mol Sci*, 23(12). doi: 10.3390/ijms23126702
38. Syu, J. P., Chi, J. T., Kung, H. N. (2016). Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. [Journal Article]. *Oncotarget*, 7(12), 14659–14672. doi: 10.18632/oncotarget.7406
39. Wang, J., Jackson, M. F., Xie, Y. F. (2016). Glia and TRPM2 Channels in Plasticity of Central Nervous System and Alzheimer's Diseases. [Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review]. *Neural Plast*, 2016, 1680905. doi: 10.1155/2016/1680905
40. Wang, J., Lin, D., Peng, H., Huang, Y., Huang, J., Gu, J. (2013). Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. [Journal Article; Research Support, Non-U.S. Gov't]. *Cell Death Dis*, 4(12), e945. doi: 10.1038/cddis.2013.474

41. Wang, L., Negro, R., Wu, H. (2020). TRPM2, linking oxidative stress and Ca(2+) permeation to NLRP3 inflammasome activation. [Journal Article; Review]. *Curr Opin Immunol*, 62, 131–135. doi: 10.1016/j.coi.2020.01.005
42. Wang, N., Wang, J., Wang, P., Ji, N., Yue, S. (2023). Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma. [Journal Article; Research Support, Non-U.S. Gov't]. *Anal Chem*, 95(31), 11567–11571. doi: 10.1021/acs.analchem.3c00967
43. Wehage, E., Eisfeld, J., Heiner, I., Jungling, E., Zitt, C., Luckhoff, A. (2002). Activation of the cation channel long transient receptor potential channel 2 (LTRPC2) by hydrogen peroxide. A splice variant reveals a mode of activation independent of ADP-ribose. [Journal Article; Research Support, Non-U.S. Gov't]. *J Biol Chem*, 277(26), 23150–23156. doi: 10.1074/jbc.M112096200
44. Weng, Y., Pan, C., Shen, Z., Chen, S., Xu, L., Dong, X., Chen, J. (2022). Identification of Potential WSB1 Inhibitors by AlphaFold Modeling, Virtual Screening, and Molecular Dynamics Simulation Studies. [Journal Article]. *Evid Based Complement Alternat Med*, 2022, 4629392. doi: 10.1155/2022/4629392
45. Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., Daldrup-Link, H. E. (2021). Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review]. *Pharmacol Res*, 171, 105780. doi: 10.1016/j.phrs.2021.105780
46. Yang, H., Hu, Y., Weng, M., Liu, X., Wan, P., Hu, Y., Ma, M., Zhang, Y., Xia, H., Lv, K. (2022). Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer. [Journal Article; Research Support, Non-U.S. Gov't]. *J Adv Res*, 37, 91–106. doi: 10.1016/j.jare.2021.10.001
47. Ye, P., Fang, Q., Hu, X., Zou, W., Huang, M., Ke, M., Li, Y., Liu, M., Cai, X., Zhang, C., Hua, N., Al-Sheikh, U., Liu, X., Yu, P., Jiang, P., Pan, P. Y., Luo, J., Jiang, L. H., Xu, S., Fang, E. F., Su, H., Kang, L., Yang, W. (2023). TRPM2 as a conserved gatekeeper determines the vulnerability of DA neurons by mediating ROS sensing and calcium dyshomeostasis. [Journal Article]. *Prog Neurobiol*, 231, 102530. doi: 10.1016/j.pneurobio.2023.102530
48. Zelentsova, A. S., Deykin, A. V., Soldatov, V. O., Ulezko, A. A., Borisova, A. Y., Belyaeva, V. S., Skorkina, M. Y., Angelova, P. R. (2022). P2X7 Receptor and Purinergic Signaling: Orchestrating Mitochondrial Dysfunction in Neurodegenerative Diseases. [Journal Article; Research Support, Non-U.S. Gov't; Review]. *eNeuro*, 9(6). doi: 10.1523/ENEURO.0092-22.2022
49. Zhu, J., Jin, M., Wang, J., Zhang, H., Wu, Y., Li, D., Ji, X., Yang, H., Yin, C., Ren, T., Xing, J. (2018). TNFalpha induces Ca(2+) influx to accelerate extrinsic apoptosis in hepatocellular carcinoma cells. [Journal Article]. *J Exp Clin Cancer Res*, 37(1), 43. doi: 10.1186/s13046-018-0714-6
50. Zhu, X., Zuo, L. (2013). Characterization of oxygen radical formation mechanism at early cardiac ischemia. [Journal Article; Research Support, Non-U.S. Gov't]. *Cell Death Dis*, 4(9), e787. doi: 10.1038/cddis.2013.313



# Figures





Figure 1

Effects of TMZ on the cell viability, mitochondria function and intracellular ROS levels in U87MG cells under hypoxia and normoxia. (A) U87MG cells were cultured at different concentrations of TMZ for 24 hours under normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>), and then subjected to WST-1 Assay. \*\*p < 0.01 vs.


normoxia group. (B) After exposition to normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>) for 24 hours, U87MG cells were treated with TMZ for the indicated time points and measured the cell viability by WST-1 Kit. \*\*p < 0.01 vs. normoxia group. (C) U87MG cells were respectively treated with TMZ for 0, 24 and 48 hours, then stained with JC-1 and observed by fluorescence microscope. Green fluorescence represents JC-1 monomer, indicating impaired mitochondrial membrane potential ( $\Delta\Psi_m$ ). (D) The relative amounts of JC-1 green fluorescence were analyzed. (E) The intracellular ROS scavenging activity was measured according to the H2DCF-DA method. \*\*p < 0.01 vs. normoxia group (0 hour); ##p < 0.01 vs. normoxia group (24 hours);  $\Delta\Delta$ p < 0.01 vs. normoxia group (48 hours). Data was shown as mean  $\pm$  SD, and analyzed by One-way ANOVA.



**Figure 2**


**ROS participates in hypoxia-mediated TRPM2 protein expression in U87MG cells.** (A) U87MG cells were respectively cultivated at different times under normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>) and detected for the intracellular ROS levels according to the H2DCF-DA method. (B) U87MG cells were incubated at different times under hypoxia (2.5% O<sub>2</sub>), and TRPM2 expression was semi-quantified by western blot analysis. (C) The relative amounts of TRPM2 protein were analyzed by comparing to GAPDH. \*\*p < 0.01

vs normoxia group (0 hour); ## $p < 0.01$  vs normoxia group (12 hours). (D) U87MG cells were respectively treated with or without 100 $\mu$ M N-acetyl-L-cysteine (NAC) for 24 hours under normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>), and the protein levels of TRPM2 were semi-quantified by western blot analysis. GAPDH was used as loading control for each lane. (E) Densitometric analysis of TRPM2 expression was executed by comparing with GAPDH. \*\* $p < 0.01$  vs normoxia group (without NAC); ## $p < 0.01$  vs hypoxia group (without NAC). Each bar represents the mean  $\pm$  SD from three independent experiments.



**Figure 3**

**TRPM2 is positive correlation with TMZ resistance-associated protein in glioma cells.** (A) Correlation analysis of TRPM2 and MGMT in diverse tumor types. (B) Relationship between TRPM2 and MGMT expression in glioma group used the TIMER 2.0 database.



**Figure 4**

**TRPM2 is linked to TMZ resistance in glioma cells.** (A) The protein levels of TRPM2 and MGMT were detected by western blot in five glioblastoma tissues. (B) The relevance between TRPM2 and MGMT in human glioblastoma tissues was analyzed. (C) After incubation for 24 hours under normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>), hypoxic cells were treated with or without 2-APB (inhibitor of TRPM2) for 24 hours, and the equal volume of PBS was added in normoxia group. The protein levels of MSH3, APNG and

MGMT were semi-quantified by western blot analysis. GAPDH was used as loading control for each lane. (D, E and F) Densitometric analysis of MSH3, APNG and MGMT protein levels was performed by comparing with GAPDH. \*\*p < 0.01 vs normoxia group; ###p < 0.01 vs hypoxia group (without 2-APB). Each bar represents the mean  $\pm$  SD from three independent experiments.





Figure 5

**TRPM2-dependent increase of intracellular calcium is implicated in protection of mitochondrial function under Hypoxia.** After incubation for 24 hours under normoxia (21% O<sub>2</sub>) or hypoxia (2.5% O<sub>2</sub>), U87MG cells were respectively treated with PBS, TMZ (200 μM) alone, TMZ (200 μM) plus 2-APB (100 μM) for 24 hours. (A) The cells were stained with Fluo-3 AM (2 μM for 60 min), and the representative images were observed in the fluorescence microscope. (B) U87MG cells were stained with JC-1 and then examined by fluorescence microscope. (C) Changes of the intensity of [Ca<sup>2+</sup>]<sub>i</sub> were shown by columns. (D) The relative amounts of JC-1 green fluorescence were measured. Te scale bar = 50 μm. Objective: 20x oil. Each bar represents the mean ± SD from three independent experiments. \*\*p < 0.01 vs. PBS (normoxia group); ##p < 0.01 vs. TMZ alone (normoxia group); ΔΔp < 0.01 vs. TMZ alone (hypoxia group).



**Figure 6**

**Hypoxia improves TMZ resistance to U87MG cells through ROS - mediated increase of TRPM2 expression.** After incubation for 24 hours under hypoxia (2.5% O<sub>2</sub>), U87MG cells were respectively treated with PBS, TMZ (200 μM) alone, NAC (100 μM) alone, 2-APB (100 μM) alone, TMZ (200 μM) plus 2-APB (100 μM) and TMZ (200 μM) plus NAC (100 μM) for 24 hours. (A) The representative images were observed by the inverted microscope. (B) Quantification of neurite length was executed. Te scale bar = 50 μm. Objective: 20x oil. Each experiment was performed for three times. Data was shown as mean ± SD. \*\*p < 0.01 vs Control; ##p < 0.01 vs TMZ alone group.